Speaker Profile
M.D., Ph.D., Founder & CEO, n-Lorem Foundation
Biography
Dr. Stanley Crooke is founder, chairman and chief executive officer of n-Lorem, a nonprofit foundation focused on providing treatments for patients with nano-rare disease patients (1 to 30 patients worldwide), which he initiated in January 2020.
Prior to n- Lorem, Dr. Crooke founded and was Chairman and Chief Executive Officer and Lead Scientist of Ionis Pharmaceuticals. During his tenure at Ionis, he led the scientific development of a new platform for drug discovery, antisense technology and the creation of one of the largest and more advanced development pipelines in the biotechnology industry, and commercialized several antisense drugs including, SPINRAZA® (nusinersen), TEGSEDI™ (inotersen) and others. Early in Dr. Crooke’s career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D (president) at SmithKline Beckman (now GSK). During his tenure at SKB, Dr. Crooke led the restructuring of R&D and the development of several drugs that were commercialized.
Dr. Crooke has also contemporaneously led a successful academic career becoming a full professor at Baylor College of Medicine and the University of Pennsylvania Medical School where he trained a number of Ph.D. students and won several teaching awards. Dr. Crooke has been an active scientist throughout his career as well.
Dr. Crooke has received a number of awards, most recently, the Indiana University School of Medicine Steven C. Beering Award, the Prix Galien Roy Vagelos Pro Bono Humanum Award, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society, the Scrip Lifetime Achievement Award and the 2019 Massry Prize.
Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine, where he currently serves on the Board of Advisors. In 2021, Dr. Crooke has been named Distinguished Alumnus of both Baylor College of Medicine’s Graduate and Medical schools and named one of the 20 of the most influential biopharma R&D executives by Endpoints News. He has published nearly 600 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 23 drugs that have been commercialized.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Wendy Chung, Boston Children's / Harvard
PMWC Award Ceremony
• Wendy Chung, Boston Children's / Harvard (Pioneer)
• Eric Lander, Broad Institute (Pioneer)
Featured Speakers
• Wendy Chung, Boston Children's / Harvard
• Eric Lander, Broad Institute
• Zhanzhi (Mike) Hu, Project GUARDIAN / Columbia
• Tippi MacKenzie, UCSF
• Ryan Taft, Genetic Alliance
• Heidi Cope, RTI International
• Michele Caggana, NY State DOH Wadsworth Center
• Elad Ziv, UCSF
• Scott Grosse, University of Minnesota
• Mike Talkowski, Mass General / Harvard
• F. Sessions Cole, WashU
• Lee Hood, Phenome Health / ISB
• Trey Ideker, UC San Diego
• Ralph Snyderman, Duke
• Craig Mundie, Mundie & Associates
• George Church, Harvard
Beyond the Exome: Solving Undiagnosed Disease
The next layer of rare-disease diagnosis beyond standard sequencing.
Population Genomic Screening
From newborn sequencing to implementation, evidence, economics, and equity.
Structural Variants & Long Reads
Solving cases missed by conventional sequencing.
Launching the Human Phenome Initiative
From genome to phenome as a global health infrastructure challenge.
Data-Driven Health
AI, longitudinal data, and personalized clinical medicine.
Engineering the Future of Health
Genomes, cells, and engineering biology as precision medicine moves upstream.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
